Two Sigma Advisers
STRO icon

Two Sigma Advisers’s Sutro Biopharma STRO Stock Holding History

Two Sigma Advisers’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,580
Closed -$203K – 1876
2025
Q4 		$203K Sell
17,580
-6,360
-27% -$60.4K ﹤0.01% 2125
2025
Q3 		$208K Buy
23,940
+17,310
+261% +$147K ﹤0.01% 2121
2025
Q2 		$47.3K Sell
6,630
-17,460
-72% -$143K ﹤0.01% 2258
2025
Q1 		$157K Sell
24,090
-30,690
-56% -$483K ﹤0.01% 2178
2024
Q4 		$1.01M Sell
54,780
-4,310
-7% -$132K ﹤0.01% 1457
2024
Q3 		$2.04M Sell
59,090
-9,560
-14% -$375K ﹤0.01% 1048
2024
Q2 		$2.01M Buy
68,650
+1,540
+2% +$60.9K ﹤0.01% 1190
2024
Q1 		$3.79M Buy
67,110
+43,130
+180% +$1.91M 0.01% 900
2023
Q4 		$1.03M Buy
23,980
+5,460
+29% +$173K ﹤0.01% 1638
2023
Q3 		$643K Sell
18,520
-16,450
-47% -$717K ﹤0.01% 1700
2023
Q2 		$1.63M Sell
34,970
-7,160
-17% -$356K ﹤0.01% 1303
2023
Q1 		$1.95M Buy
42,130
+3,820
+10% +$242K 0.01% 1283
2022
Q4 		$3.1M Buy
38,310
+3,560
+10% +$247K 0.01% 999
2022
Q3 		$1.93M Buy
34,750
+8,700
+33% +$515K 0.01% 1188
2022
Q2 		$1.36M Buy
26,050
+15,360
+144% +$858K ﹤0.01% 1429
2022
Q1 		$879K Buy
10,690
+1,260
+13% +$120K ﹤0.01% 1700
2021
Q4 		$1.4M Sell
9,430
-6,000
-39% -$1.07M ﹤0.01% 1369
2021
Q3 		$2.92M Buy
15,430
+6,230
+68% +$1.18M 0.01% 1056
2021
Q2 		$1.71M Buy
9,200
+3,220
+54% +$630K ﹤0.01% 1368
2021
Q1 		$1.36M Buy
5,980
+1,690
+39% +$401K ﹤0.01% 1474
2020
Q4 		$931K Buy
4,290
+110
+3% +$18.2K ﹤0.01% 1594
2020
Q3 		$420K Buy
+4,180
New +$395K ﹤0.01% 1886

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Two Sigma Advisers's STRO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 17,580 shares — an estimated $203K sold.

Two Sigma Advisers first reported a position in STRO in Q3 2020 and held it in 22 quarters. The position peaked at $3.79M in Q1 2024. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 17,580 Sutro Biopharma shares in Q1 2026, an estimated $203K.
  • Two Sigma Advisers first reported a position in Sutro Biopharma in Q3 2020 and held it in 22 quarters.
  • Two Sigma Advisers's Sutro Biopharma position peaked at $3.79M in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.